Reversal of the Antithrombotic Action of New Oral Anticoagulants (REVANT)

Gines Escolar

Status and phase

Unknown

Phase 4

Conditions

Hemorrhage

Anticoagulant Overdosage

Thrombosis

Anticoagulant-induced Bleeding

Treatments

Drug: Rivaroxaban

Drug: Dabigatran

Study type

Interventional

Funder types

Other

Identifiers

NCT01478282

2010-022985-29 (EudraCT Number)

FCRB

Details and patient eligibility

About

The main goal of this study is to improve safety and efficiency of clinical practice with the new generation of oral anticoagulants.

To determine the effect of new oral anticoagulants (dabigatran and rivaroxaban) on platelets and coagulation mechanisms under flow conditions.
To evaluate the ability of the concentrates containing coagulation factors (PCCs and FVIIa) to reverse the effects induced by the new anticoagulants.

These studies will be carried out ex vivo in blood samples obtained from healthy volunteers undergoing oral anticoagulant therapy at doses of proven efficacy and safety used in previous clinical trials.

Full description

There is a lack of information on antidotes that could reverse the effects of new oral anticoagulants in patients that require a rapid restoration of their impaired hemostatic mechanisms. The present study seeks to improve the security and efficacy of the clinical practice with the new generation of oral anticoagulants.

OBJECTIVES:

To assess the action of new oral anticoagulants (dabigatran y rivaroxaban) on hemostasis with specific interest on possible interference with platelet interactions and coagulation mechanisms under flow conditions;
To evaluate comparatively the effects of coagulation factor concentrates of established efficacy (prothrombin complexes and rFVIIa) to reverse the alterations of hemostasis parameters induced by the new anticoagulants.

METHODOLOGY:

Studies will be performed ex vivo using blood samples from healthy individuals subjected to treatments with the new anticoagulants at doses of proven efficacy and safety (150mg/12 h for dabigatran and 20 mg/day for rivaroxaban). Blood samples from the participants will be spiked "in vitro" with know concentrations of the coagulation factors. Modifications in:

morphometric parameters (platelet deposition and fibrin formation) in perfusion studies under flow conditions; and
analytical tests evaluating changes in coagulation mechanisms (thrombin generation, ecarine and prothrombin times) will be determined.

Enrollment

10 estimated patients

Sex

All

Ages

21 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy volunteers ages from 21 to 60 years
Approval informed consent

Exclusion criteria

History of hepatic or kidney disease
Previous history of hemorrhagic or thrombotic disease
Pregnancy or breast feeding
Concomitant use of drugs affecting hemostasis
Use of medications of herbal treatments that could interfere with the pharmacokinetics or pharmacodynamics of the study drug (according to manufacturers label)
Practice of risky sports (during the study period)
Blood donation in the previous 3 months